Merck Animal Health Introduces SEQUIVITY™ Technology

Provides swine producers disease specific vaccines to protect herd health

MADISON, N.J., June 6, 2018 – Merck Animal Health, a global leader in vaccine development, is excited to deliver SEQUIVITY™ Technology. This innovative and highly advanced RNA Particle Technology is used to create flexible, safe and precise vaccine solutions to new and evolving disease challenges.

Vaccination is essential to disease prevention and has been key to protecting animal health. SEQUIVITY represents a technological advance within the company’s existing vaccine portfolio, with a platform that uses genetic sequences for specific antigens found in disease producing pathogens. This allows the creation of vaccines as needed in response to new or progressing diseases.

“By producing herd-specific custom vaccines, the technology enables producers and veterinarians to tackle animal health issues quickly and safely,” says Joe Roder, D.V.M., technical services manager, Merck Animal Health. “Since diseases differ around the world, the technology allows us to diagnose specific disease risks and take a targeted approach to disease control, depending on the exact needs of the country or region.”

In addition to being able to customize vaccines to meet specific threats, the SEQUIVITY platform technology can be used to provide a solution in a short period of time, where traditional vaccines can take years to develop.

How it Works: RNA Particle Technology

Vaccination mimics infection by introducing inactivated whole pathogens (antigens) into the animal to stimulate the immune system. For a conventional vaccine, the antigen is grown in the lab, deactivated or killed and then presented to the body. However, with SEQUIVITY and its revolutionary RNA Particle Technology, an electronic gene sequence is utilized.

After receiving the sequence, it is synthesized into RNA and inserted into the SEQUIVITY platform, which generates RNA particles. When injected in the animal, these particles provide instructions to the immune cells to translate the sequence into proteins which act as antigens.

Then, when challenged with an actual live pathogen, the animal’s immune system recognizes the antigen and a targeted immune response is triggered.

To learn more about SEQUIVITY and to find answers to your advanced herd health challenges, visit or contact your local Merck sales representative.

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, wellbeing and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedInFacebook, and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (